Interferon and T-Cell Lymphoma

Excerpt

To the editor: In 1984, Bunn and associates (1) reported that high-dose recombinant leukocyte A interferon was highly effective in the treatment of advanced refractory cutaneous T-cell lymphoma. However, it was difficult to assess survival. The same group, by getting more clinical experience with the drug, stated that interferon alfa-2a is a treatment of choice for patients with advanced cutaneous T-cell lymphomas refractory to chemotherapy and other standard forms of therapy (2). Based on these reports, we recently treated a patient who had Sézary syndrome refractory to previous forms of therapy with high-dose recombinant interferon alfa-2a.

A 55-year-old woman has